Clinical trials: Demyelinating Disorder
Multiple Sclerosis
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing…
- Trial name
- BRAVO (NCT00605215)
- Testing
- Laquinimod, Avonex®
- Where
- 170 sites in United States, Bulgaria and 17 more
- Volunteers
- 1,331 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Chronic Brain Injury, Cerebral Stroke
Qualitative Study Patient & Physician Experiences Botox COVID-19
During the COVID-19 pandemic and subsequent series of Lockdowns, clinic out-patient spasticity services were replaced with video based tele-consultation appointments, in order to reduce the potential risk of virus transmission…
- Conditions
- Chronic Brain Injury, Cerebral Stroke, MS (Multiple Sclerosis)
- Trial name
- QualBotoxCov (NCT05435404)
- Where
- United Kingdom
- Volunteers
- 11 people
- Sponsor
- East Kent Hospitals University NHS Foundation Trust
Guillain-Barré Syndrome
A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)
This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.
- Trial name
- NCT04035135
- Testing
- ANX005, Intravenous immunoglobulin
- Where
- 2 sites in Bangladesh, Denmark
- Volunteers
- 14 people
- Sponsor
- Annexon, Inc.
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Multiple Sclerosis
Hematopoietic Stem Cell Therapy for Patients With Multiple Sclerosis
Multiple sclerosis is disease believed to be due to immune cells, cells which normally protect the body, but are now attacking the tissue in the brain and possibly the spinal cord.
- Trial name
- NCT00278655
- Testing
- Hematopoietic stem cell transplantation
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Multiple Sclerosis
Care in Multiple Sclerosis (MS)
This study is structured around three main aims. In Aim 1, investigators will conduct community-based participatory research (CBPR) to develop culturally tailored methods to assess childhood adversity in multiple sclerosis (MS).
- Trial name
- NCT07011914
- Where
- 6 sites in United States
- Volunteers
- 300 people
- Sponsor
- NYU Langone Health
Stroke, PARKINSON DISEASE (Disorder)
Objective Longitudinal Monitoring of Postural Stability and Gait During Neurorehabilitation: Clinical Application of Instrumented Posturography and Three-Dimensional Motion Analysis
Nowadays, stroke is one of the most common leading causes of death in many countries. As the number of stroke patients is increasing, even in younger age groups, there is an increasing need to improve their rehabilitation.
- Conditions
- Stroke, PARKINSON DISEASE (Disorder), Multiple Sclerosis
- Trial name
- NCT07411664
- Testing
- Stroke posturo/3D group, Parkinson posturo/3D group, Multiple sclerosis posturo/3D group
- Where
- Hungary
- Volunteers
- 151 people
- Sponsor
- Somogy Megyei Kaposi Mór Teaching Hospital
Lysosomal Storage Disease, Metachromatic Leukodystrophy
A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)
OTL-200 is autologous CD34+ cells transduced with lentiviral vector containing human arylsulfatase A (ARSA) complementary deoxyribonucleic acid (cDNA) used for the treatment of MLD.
- Trial name
- NCT03392987
- Testing
- OTL-200
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Orchard Therapeutics
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)
SIDEC - (Subcutaneous Immunoglobulin in De-novo CIDP) ia a study designed as a randomized, parallel study with an open-label extension phase.
- Trial name
- SIDEC (NCT04589299)
- Testing
- Immunoglobulin
- Where
- 4 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Multiple Sclerosis
A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
This pilot study will establish a proof of concept for using a systems biology approach to characterize the dynamics of MS disease processes.
- Trial name
- NCT05081700
- Testing
- All patients in the study will be treated with ocrelizumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis
The Use of Technology to Improve MS Clinical Trials and Patient Care
Many patients with multiple sclerosis (MS) experience "relapses" of disease activity during which they have increased numbness, weakness, visual problems, or other symptoms.
- Trial name
- NCT02454907
- Testing
- Communication with the clinic
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
Evaluation of Clinical, Morphologic and Biochemical Markers in Multiple Sclerosis
By combining clinical, morphological and biochemical markers a better understanding of the formation and progression of multiple sclerosis (MS) should be obtained
- Trial name
- NCT04892134
- Testing
- blood sample
- Where
- Austria
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Multiple Sclerosis, Pain
Effects of Telerehabilitation-Based Motor Imagery Training on Pain in People With Multiple Sclerosis
In this studly, the effects of an 8-week telerehabilitation-based motor imagery training on pain and related factors in persons with multiple sclerosis will be investigated.
- Trial name
- NCT05326711
- Testing
- Telerehabilitation-based motor imagery training
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Dokuz Eylul University
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi
Multiple Sclerosis
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the…
- Trial name
- NCT05081271
- Testing
- Homologous booster, Heterologous booster
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Griffin Hospital
Relapsing Multiple Sclerosis
Effects of Ocrevus in Relapsing Multiple Sclerosis
The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT).
- Trial name
- MOBILE-RMS (NCT04387734)
- Testing
- Ocrelizumab, Platform
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Georgia State University
Multiple Sclerosis
Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis
The effects of multiple sclerosis (MS) on cognition, thought to occur in 50-75% of persons with MS, have gained increasing recognition as one of the major disabling symptoms of the disease.
- Trial name
- NCT03200899
- Testing
- MAPSS-MS, Usual Care plus computer games
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- University of Texas at Austin
Multiple Sclerosis
Pharmacogenomics of Drug Safety in Multiple Sclerosis
To investigate whether genotypic differences can be identified between MS patients developing 'liver injury' (defined as ALT levels five times the upper normal limit and above) compared to those not developing liver injury after…
- Trial name
- NCT01118130
- Where
- 5 sites in Canada
- Volunteers
- 300 people
- Sponsor
- University of British Columbia
Multiple Sclerosis
Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training
Patients diagnosed with any type of multiple sclerosis (MS) who show objective evidence of attention problems will be randomized to standard medical care (treatment as usual) or attention training, which will be completed at…
- Trial name
- NCT02634567
- Testing
- Cogmed Working Memory Training (CWMT)
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- London Health Sciences Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.